BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pieske B, Wachter R, Shah SJ, Baldridge A, Szeczoedy P, Ibram G, Shi V, Zhao Z, Cowie MR; PARALLAX Investigators and Committee members. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial. JAMA 2021;326:1919-29. [PMID: 34783839 DOI: 10.1001/jama.2021.18463] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Perrone-filardi P, Paolillo S, Agostoni P, Basile C, Basso C, Barillà F, Correale M, Curcio A, Mancone M, Merlo M, Metra M, Muscoli S, Nodari S, Palazzuoli A, Pedrinelli R, Pontremoli R, Senni M, Volpe M, Indolfi C, Sinagra G. Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology. European Journal of Internal Medicine 2022. [DOI: 10.1016/j.ejim.2022.04.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Numata G, Takimoto E. Cyclic GMP and PKG Signaling in Heart Failure. Front Pharmacol 2022;13:792798. [DOI: 10.3389/fphar.2022.792798] [Reference Citation Analysis]
3 . Sacubitril/Valsartan: PARALLAX-Studie mit gemischten Ergebnissen. Dtsch Med Wochenschr 2022;147:444-444. [DOI: 10.1055/a-1711-9690] [Reference Citation Analysis]
4 Weerts J, Mourmans SGJ, Barandiarán Aizpurua A, Schroen BLM, Knackstedt C, Eringa E, Houben AJHM, van Empel VPM. The Role of Systemic Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction. Biomolecules 2022;12:278. [DOI: 10.3390/biom12020278] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Nolan T. Tom Nolan's research reviews-26 November 2021. BMJ 2021;375:n2938. [PMID: 34836915 DOI: 10.1136/bmj.n2938] [Reference Citation Analysis]
6 Abdin A, Schulz M, Riemer U, Hadëri B, Wachter R, Laufs U, Bauersachs J, Kindermann I, Vukadinović D, Böhm M. Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials. ESC Heart Fail 2022. [PMID: 35921043 DOI: 10.1002/ehf2.14097] [Reference Citation Analysis]
7 Raschi E, Diemberger I, Sabatino M, Poluzzi E, De Ponti F, Potena L. Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction. Expert Opin Pharmacother 2022;:1-18. [PMID: 35050813 DOI: 10.1080/14656566.2022.2027909] [Reference Citation Analysis]
8 Palandri C, Santini L, Argirò A, Margara F, Doste R, Bueno-Orovio A, Olivotto I, Coppini R. Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside. Drugs 2022;82:889-912. [PMID: 35696053 DOI: 10.1007/s40265-022-01728-w] [Reference Citation Analysis]
9 Zhang M, Guo F, Li X, Xian M, Wang T, Wu H, Wei J, Huang Y, Cui X, Wu S, Gong M, Yang H. Yi-Xin-Shu capsule ameliorates cardiac hypertrophy by regulating RB/HDAC1/GATA4 signaling pathway based on proteomic and mass spectrometry image analysis. Phytomedicine 2022;103:154185. [DOI: 10.1016/j.phymed.2022.154185] [Reference Citation Analysis]